Reduced activity of the kallikrein-kinin system predominates over renin-angiotensin system overactivity in all conditions of sodium balance in essential hypertensives and family-related hypertension

Journal of Hypertension

Volumn 21, Issue 2, 2003, Pages 411-417

  Sànchez, Ramiro ^a   Nolly, Hector ^b   Giannone, Carlos ^a   Baglivo, Hugo P ^a   Ramírez, Agustín J ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^b Universidad de Cuyo   (Argentina)

Author keywords

Hypertensive offspring; Renal hemodynamics; Renin angiotensin aldosterone system; Sodium balance; Urinary kallikrein

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; SODIUM; TISSUE KALLIKREIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION; HOMEOSTASIS; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROGENY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BALANCE; SODIUM LOAD;

EID: 0037331576     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200302000-00034     Document Type: Article

References (27)

1. MacGregor GA. Sodium is more important than calcium in essential hypertension. Hypertension 1985; 7:628-640.
2. MacGregor GA. Salt and hypertension. Br J Clin Pharmacol 1986; 21 (suppl 2):123s-128s.
3. Culter JA, Follmann D, Allender PS. Randomized trials of sodium restriction: an overview. Am J Clin Nutr 1997; 65 (suppl 1):643s-651s.
4. + restriction. J Hypertens 1996; 14:1287-1291.
5. He FJ, Markandu ND, MacGregor GA. Importance of the renin system for determining blood pressure fall with acute salt restriction in hypertensive and normotensive whites. Hypertension 2001; 38:321-325.
6. Edling O, Gohlke P, Paul M, Rettig R, Strauss HM, Steckelings UM, Unger T. The renin angiotensin system: physiology and pathophysiology. Physiology of the renin angiotensin system. In: Schactner M (editor): ACA inhibitors: current use and future prospects. London: Martin Dunitz; 1995, pp. 3-41.
7. Siragy HM. Evidence that intrarenal bradykinin plays a role in regulation of renal function. Am J Physiol 1993; 265 (4 pt 1):E648-E654.
8. Margolius HS. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 1995; 26:221-229.
9. Siragy HM, Jaffa AA, Margolius HS. Stimulation of renal interstitial bradykinin by sodium depletion. Am J Hypertens 1993; 6:863-866.
10. Carretero OA, Scicli AG. Local hormonal factors (intracrine, autocrine and paracrine) in hypertension. Hypertension 1991; 18 (suppl 1):158-169.
11. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995, 26:236-243.
12. Havlik RJ, Garrison RJ, Feinleib M, Kannel WB, Castelli WP, McNamara PM. Blood pressure aggregation in families. Am J Epidemiol 1979; 110:304-312.
13. Sànchez R, Giménez MI, Migliorini M, Giannone C, Ramírez AJ, Weder AB. Erythrocyte sodium-lithium countertransport in non-modulating offspring and essential hypertensive individuals. Hypertension 1997; 30 (Part 1):99-105.
14. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin MC, Skuppin J, et al. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 1996; 14:199-207.
15. Nolly HL, Scicli AG, Scicli G, Carretero OA. Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein. Circ Res 1985; 56:816-821.
16. Schnurr E, Lahma W, Kuppers H. Measurements of renal clearence of inulin and PAH in the steady-state without urine collection. Clin Nephrol 1980; 13:26-29.
17. Widgren BR, Herlitz H, Aurell M, Berglund G, Wikstrand J, Andersson OK. Increased systemic and renal vascular sensitivity to angiotensin II in normotensive men with positive family histories of hypertension. Am J Hypertens 1992; 5:167-174.
18. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash Ko, et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989; 13:3-8.
19. Klingbeil AU, Jacobi J, Langenfeld MR, John S, Hilgers KF, Scmieder RE. Enhanced antinatriuresis in response to angiotensin II in essential hypertension. Am J Hypertens 2000; 13:986-993.
20. Schlaich MP, Klingbeil AU, Jacobi J, Delles C, Schneider MP, Schmidt BMW, Schmieder RE. Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. J Hypertens 2002; 20:117-124.
21. Cervenka L, Maly J, Karasovà L, Simovà M, Vitko S, El-Dahr SS. Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. Hypertension 2001, 37:967-973.
22. McGarvey ST, Zinner SH, Margolius HS. Urinary kallikrein and blood pressure in infants and children. In: Limura O, Margolius HS (editors): Renal function, hypertension and kallikrein-kinin systems. Tokyo: Kokusen.Sha; 1988, pp. 161-168.
23. Kailasam MT, Martinez JA, Cervenka JH, Yen SSC, O'Connor DT, Parmer RJ. Racial differences in renal kallikrein excretion: effect of the ovulatory cycle. Kidney Int 1998; 5:1652-1658.
24. Stachenfeld NS, DiPietro L, Kokoszka CA, Silva C, Keefe DL, Nadel ER. Physiological variability of fluid-regulation hormones in young women. J Appl Physiol 1999; 86:1092-1096.
25. Siragy HM, de Gasparo M, El-Kersh M, Carey RM. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001; 38:183-186.
26. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharamacol Rev 1992; 44:1-80.
27. Yu H, Carretero OA, Juncos LA, Garvin JL. Biphasic effect of bradykinin on rabbit afferent arterioles. Hypertension 1998; 32:287-292.